Non-Pegylated Liposomal Doxorubicin in Combination with Cyclophosphamide or Docetaxel as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis
Restricted accessResearch articleFirst published online July, 2009
Non-Pegylated Liposomal Doxorubicin in Combination with Cyclophosphamide or Docetaxel as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis
Anthracyclines such as doxorubicin play a central role in the management of advanced breast cancer. Unfortunately, the clinical benefits of anthracyclines are limited by cardiotoxicity that can lead to the development of potentially fatal congestive heart failure. In order to limit anthracycline-related cardiotoxicity, liposomal formulations of doxorubicin have been developed. This retrospective analysis evaluated the experience obtained with non-pegylated liposomal doxorubicin as first-line therapy in 34 patients with metastatic breast cancer.
Methods
Patients received non-pegylated liposomal doxorubicin in combination with either cyclophosphamide (n = 14) or docetaxel (n = 20) for up to eight cycles, and efficacy and safety were assessed according to standard criteria.
Results
The overall response rate was 71%. The median progression-free survival was 8 months in patients receiving non-pegylated liposomal doxorubicin plus cyclophosphamide and 13.8 months in those receiving non-pegylated liposomal doxorubicin plus docetaxel (P = 0.2). The most commonly observed toxicities were grade 1–2 leucopenia, alopecia, nausea and vomiting; no grade 3–4 toxicities were observed. Overall, three patients (9%) experienced grade 1 cardiac toxicity.
Conclusions
Our results support the use of non-pegylated liposomal doxorubicin as an alternative to conventional doxorubicin formulations in combination regimens for the first-line therapy of metastatic breast cancer.
GreenbergP.A., HortobagyiG.N., SmithT.L., ZieglerL.D., FryeD.K., BuzdarA.U.: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 14: 2197–2205, 1996.
5.
ValeroV., HortobagyiG.N.: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?J Clin Oncol, 21: 959–962, 2003.
6.
SledgeG.W.: The continuing problem of cardiac toxicity. Semin Oncol, 28(4 Suppl 12): 1, 2001.
7.
PragaC., BerettaG., VigoP.L., LenazG.R., PolliniC., BonadonnaG., CanettaR., CastellaniR., VillaE., GallagherC.G., von MelchnerH., HayatM., RibaudP., De WaschG., MattssonW., HeinzR., WaldnerR., KolaricK., BuehnerR., Ten Bokkel-HuyninckW., PerevodchikovaN.I., ManziukL.A., SennH.J., MayrA.C.: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep, 63: 827–834, 1979.
8.
Von HoffD.D., LayardM.W., BasaP., DavisH.L.Jr., Von HoffA.L., RozencweigM., MuggiaF.M.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 91: 710–717, 1979.
9.
SchwartzR.G., McKenzieW.B., AlexanderJ., SagerP., D'SouzaA., ManatungaA., SchwartzP.E., BergerH.J., SetaroJ., SurkinL.: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med, 82: 1109–1118, 1987.
DandoT.M., KeatingG.M.: Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am J Cancer, 4: 193–206, 2005.
12.
BatistG., RamakrishnanG., RaoC.S., ChandrasekharanA., GutheilJ., GuthrieT., ShahP., KhojastehA., NairM.K., HoelzerK., TkaczukK., ParkY.C., LeeL.W.: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol, 19: 1444–1454, 2001.
13.
HarrisL., BatistG., BeitR., RoviraD., NavariR., AzarniaN., WellesL., WinerE.; TLC D-99 Study Group: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer, 94: 25–36, 2002.
14.
BatistG., HarrisL., AzarniaN., LeeL.W., Daza-RamirezP.: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs, 17: 587–595, 2006.
15.
van DalenE.C., MichielsE.M.C., CaronH.N., KremerL.C.M.: Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 4: CD005006, 2006.
16.
World Health Organization: Handbook for Reporting Results of Cancer Treatment.WHO, Geneva, 1979.
17.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
18.
ChanS., DavidsonN., JuozaityeE., ErdkampF., PluzanskaA., AzarniaN., LeeL.W.: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for therapy for metastatic breast cancer. Ann Oncol, 15: 1527–1534, 2004.
19.
BiganzoliL., CuferT., BruningP., ColemanR., DuchateauL., CalvertA.H., GamucciT., TwelvesC., FargeotP., EpelbaumR., LohrischC., PiccartM.J.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line therapy in metastatic breast cancer. The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase II trial. J Clin Oncol, 20: 3114–3121, 2002.
20.
LuckH., ThomssenC., UntchM., KuhnW., EidtmamH., Du BoisA.: Multicentric Phase III Study in First Line Treatment of Advanced Metastatic Breast Cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group. 2000 ASCO Annual Meeting. Proc Am Soc Clin Oncol, 19: 2000 (abstract 2080).
21.
CarmichaelJ.: UKCCCR Trial of Epirubicin and Cyclophosphamide (EC) Vs. Epirubicin and Taxol® in the First-Line Treatment of Women with Metastatic Breast Cancer (MBC). 2001 ASCO annual Meeting. Proc Am Soc Clin Oncol, 20: 2001 (abstract 84).
22.
van DalenE.C., CaronH.N., DickinsonH.O., KremerL.C.: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 16: CD003917, 2008.
23.
MartyM., EspiéM., LlombartA., MonnierA., RapoportB.L., StahalovaV; Dexrazoxane Study Group: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol, 17: 614–622, 2006.
24.
Del BarcoS., ColomerR., CalvoL., TusquetsI., AdroverE., SánchezP., RifàJ., De la HabaJ., VirizuelaJ.A.: Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res Treat, 116(2): 351–359, 2009.
25.
SchmidP., KrockerJ., JehnC., MichniewiczK., Lehenbauer-DehmS., EggemannH., HeilmannV., KümmelS., SchulzC.O., DieingA., WischnewskyM.B., HauptmannS., EllingD., PossingerK., FlathB.: Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol, 16: 1624–1631, 2005.
